Loading...
Skip to Content
Sale

Retatrutide - 10MG


$100 $75 CAD

Retatrutide is a next-generation research peptide studied for its multi-receptor activity involving GLP-1, GIP, and glucagon pathways. In preclinical and clinical research settings, Retatrutide has attracted attention for its potential role in metabolic regulation, appetite control, and body composition research. Its unique triple-agonist mechanism makes it a valuable compound for investigators exploring advanced metabolic and endocrine pathways.


99%+ Purity
Certificate of Analysis: Here

Free Shipping Over $300

We ship from Kelowna, Calgary & Regina. Same day shipping (from BC) in Canada on orders placed by 1pm PST (4pm EST).

7 Day Moneyback

Shipment Protection on all orders.

Guaranteed 99%+ Purity

Third party tested, not once - but TWICE.

What is Retatrutide?

Retatrutide is a next-generation peptide that acts on GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-action mechanism enhances insulin sensitivity, controls appetite, and accelerates fat metabolism. As one of the most advanced peptides for weight loss, Retatrutide is designed to support overall metabolic health while promoting effective weight management.

How Does Retatrutide Work?

Retatrutide’s unique triple-receptor mechanism targets the following: GLP-1 Receptor: Regulates blood sugar and enhances insulin sensitivity. GIP Receptor: Controls appetite and promotes satiety, reducing cravings. Glucagon Receptor: Boosts fat burning and accelerates metabolic rate. This combined action makes Retatrutide highly effective for weight loss, blood sugar control, and overall metabolic health.

Pharmacokinetics (PK) Summary

Peak Concentration: Peak plasma concentrations are reached roughly 24 to 72 hours after subcutaneous injection.
Metabolism: Like other therapeutic peptides, it is cleared via proteolytic degradation of the peptide backbone and beta-oxidation of the fatty acid side chain.
Half-Life: ~144 hours (6 days), supporting a steady-state concentration with weekly dosing.

Research Status and Safety

Retatrutide is currently in Phase 3 clinical trials (the TRIUMPH program). While its safety profile is largely consistent with other incretin mimetics (nausea, diarrhea), the glucagon component introduces a unique observation: a dose-dependent, transient increase in resting heart rate, which typically peaks around week 24 before declining.


Disclaimer: All products sold from PepStudio.ca are strictly for research and laboratory use only. They are not intended for human or animal consumption, medical use, or diagnostic purposes. All handling and use must comply with applicable research and laboratory regulations.

Shopping Cart

✕